By Dave Levitan, published on January 1, 2010 - last reviewed on March 30, 2010
For the approximately 3 percent of the population who suffer from the contested condition fibromyalgia, the pain is very real. An understanding of just where the diffuse, often body-wide distress comes from has been elusive, but new research pins the tail on dopamine.
Researchers at Louisiana State University confirmed previous findings that patients with fibromyalgia have reduced gray-matter density in certain areas of the brain, and also found a correlation between those diminished brain regions and reduced levels of dopamine metabolism. Decreased activity of this neurotransmitter, which is generally associated with pleasure responses and reward pathways, may be causing the structural changes, and thus the fibromyalgia.
Lead author Patrick Wood says investigations into drugs used to treat fibromyalgia should focus more closely on dopamine. "Dopamine has a major role in pain control," he says.
There is no pharmaceutical intervention for fibromyalgia, and dopamine drugs may be a long way off. Fibromyalgia expert Fred Friedburg of Stony Brook University describes the cognitive-behavioral approach to treating the difficult condition.